Cargando…

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study

BACKGROUND: Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known. METHODS: In this retrospective cohort study, standardised data were collected from pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raman, Lavanya, Stewart, Iain, Barratt, Shaney L., Chua, Felix, Chaudhuri, Nazia, Crawshaw, Anjali, Gibbons, Michael, Hogben, Charlotte, Hoyles, Rachel, Kouranos, Vasilis, Martinovic, Jennifer, Mulholland, Sarah, Myall, Katherine J., Naqvi, Marium, Renzoni, Elisabetta A., Saunders, Peter, Steward, Matthew, Suresh, Dharmic, Thillai, Muhunthan, Wells, Athol U., West, Alex, Mitchell, Jane A., George, Peter M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026008/ https://www.ncbi.nlm.nih.gov/pubmed/36949962 http://dx.doi.org/10.1183/23120541.00423-2022

Ejemplares similares

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
por: Fletcher, Sophie V., et al.
Publicado: (2018)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

The burden of progressive fibrotic interstitial lung disease across the UK
por: Simpson, Thomas, et al.
Publicado: (2021)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Readily accessible CT scoring method to quantify fibrosis in IPF
por: Fraser, Emily, et al.
Publicado: (2020)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Quality improvement in Respiratory Medicine: Designing and implementing a bronchoscopy checklist at Southend University Hospital
por: Thillai, Muhunthan, et al.
Publicado: (2013)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-centre cohort study
por: Achaiah, Andrew, et al.
Publicado: (2023)

The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications
por: Wells, Athol U
Publicado: (2013)

P249 Predictors of adverse outcome in sarcoidosis complicated by chronic pulmonary aspergillosis
por: Nwankwo, Lisa, et al.
Publicado: (2022)

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
por: Zulfikar, Sabrina, et al.
Publicado: (2020)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis
por: Mikolasch, Theresia A., et al.
Publicado: (2022)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management
por: Kouranos, Vasileios, et al.
Publicado: (2017)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern
por: Achaiah, Andrew, et al.
Publicado: (2021)

Historical eye on IPF: a cohort study redefining the mortality scenario
por: Tomassetti, Sara, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Comment from the Editor of the Special Issue: “Lung Disease on COPD, Asthma, Bronchiectasis, Lung Cancer Screening, IPF”
por: Chaudhuri, Nazia
Publicado: (2019)

Health-related quality of life in cardiac sarcoidosis: a systematic review
por: Quijano-Campos, Juan Carlos, et al.
Publicado: (2023)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study
por: Nolan, Claire M, et al.
Publicado: (2021)

Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment
por: Myall, Katherine Jane, et al.
Publicado: (2021)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
por: Sakkat, Abdullah, et al.
Publicado: (2022)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

Highlights of HRCT imaging in IPF
por: Sverzellati, N
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ja7mai8d6trpvrcaf6aviotmta